In biotech, it's a seller's market for machine learning know-how

The biotech applications of machine learning have weathered enough of the hype cycle that serious drug developers are embracing the technology’s potential. The thing is, so too is every other industry, which puts biotech in a tough competition for a finite amount of talent.

“The problem is when they go, ‘Hey, you have to pay me a lot.’ And I’m like, ‘Wait a second, you’re a 23-year-old, I’m not paying you a lot,’” said Christoph Lengauer, president and co-founder of Celsius Therapeutics. “But then they go, like, ‘Hey, you don’t have anyone else to hire but me.’”

Lengauer joined STAT’s Casey Ross and a panel of biotech executives to discuss the hype, hypotheses, and hiring woes when it comes to machine learning in drug discovery. And you can watch the entire event here.